Stryker Corporation

Stryker Corporation

SYKNYSEHealthcare
$294.66
up +1.43 (+0.49%)

1-Year Price

-19.08% past year
Stryker Corporation (SYK) 1-year price chart: down 19.08% from $364.15 on Oct 2025 to $294.66 on Oct 2026. Closing range $269.75 to $388.35.

EquityGlimpse Score

Overall
6.0/10
Wide Moat

Strong, durable competitive advantages versus peers.

Growth
5

Valuation, profitability, financial health, dividend and sentiment scores for Stryker Corporation (SYK) are available to EquityGlimpse members.

Market Cap
113.02B
P/E Ratio
41.40
EPS
$8.49
52W High
$392.55
52W Low
$267
Volume
3.38M
Beta
0.78
Dividend Yield
0.96%
Fair value estimate: sign up to see
Is SYK over- or undervalued? Run DCF and multiples models on EquityGlimpse.
See fair value

Key Financial Metrics

Price to Sales
5.35
Price to Book
5.99
EV/EBITDA
23.23
Free CF per Share
$11.21
Op. CF per Share
$13.20
Debt to Equity
0.73
Gross Margin
63.96%
Net Margin
12.92%

About Stryker Corporation

Stryker Corporation functions as a prominent medical technology enterprise, with its operations structured across two main divisions. The Orthopaedics and Spine segment specializes in providing implants for joint replacement procedures (including hips and knees), as well as solutions for trauma and extremities surgeries. This division also furnishes a comprehensive suite of spinal implant products, such as cervical, thoracolumbar, and interbody systems, utilized in addressing spinal injuries, deformities, and degenerative conditions. The MedSurg and Neurotechnology division offers an extensive array of products, encompassing advanced surgical equipment, surgical navigation systems, endoscopic and communication tools, patient handling devices, emergency medical apparatus, and critical care disposable items. This segment also deals in reprocessed and remanufactured medical devices, catering to various medical specialties. Furthermore, its neurotechnology offerings include devices for minimally invasive endovascular techniques, instruments for brain and open skull-based surgical interventions, and orthobiologic and biosurgery products like synthetic bone grafts and vertebral augmentation solutions. It also provides specialized minimally invasive products for treating acute ischemic and hemorrhagic strokes, alongside craniomaxillofacial implants, which include cranial, maxillofacial, and chest wall devices, in addition to dural substitutes and sealants. Stryker distributes its diverse portfolio to medical professionals, hospitals, and other healthcare institutions in approximately 75 countries, leveraging its network of company-owned subsidiaries, regional branches, and independent dealers and distributors. Established in 1941, Stryker Corporation is headquartered in Kalamazoo, Michigan.

CEO
Kevin A. Lobo
Industry
Medical - Devices
Employees
56,000
IPO Date
1980-03-17
Country
US
Unlock Full Analysis

Get the complete picture on Stryker Corporation

Sign up for EquityGlimpse to access deep fundamental data, AI reports, valuation models, and real-time tracking for SYK and 8,500+ other stocks.

30 Years of Financials
Income statements, balance sheets, and cash flows with 70+ interactive charts
AI-Powered Analysis
Generate professional research reports with 15+ AI models
DCF Valuation
Run discounted cash flow models with customizable assumptions
Portfolio Tracking
Track real-time P&L, sector allocation, and dividend projections
Earnings Intelligence
Surprise tracking, revision momentum, and whisper estimates
Insider & Congress Trades
Monitor what insiders and Congress members are buying and selling

Starting at $8.25/month. 7-day free trial. Cancel anytime.